Drug intelligence / Profile preview

indium In 111 oxyquinoline labeled leukocytes

Development stage
Unknown
Lead developer
GE Healthcare
Modality
Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cell Therapies
Administration
Intravenous
01

Overview

Indium-111-labeled leukocytes (indium In 111 oxyquinoline labeled leukocytes) is a diagnostic radiopharmaceutical imaging agent used for the scintigraphic localization of inflammatory processes and occult infections. The procedure involves the ex vivo labeling of a patient's autologous white blood cells (leukocytes) with indium-111 oxine (oxyquinoline), which are then reinjected into the patient. These radiolabeled cells migrate to and accumulate at sites of active infection or inflammation through natural chemotactic mechanisms. Imaging is typically performed 24 hours post-injection using a gamma camera to detect the gamma emissions of indium-111. It is a gold-standard diagnostic tool for identifying conditions such as osteomyelitis, prosthetic joint infections, vascular graft infections, and abdominal abscesses, offering high sensitivity and specificity for acute infectious processes.

Brand names
Indium In 111 Oxyquinoline
Other names
indium-111-labeled white blood cellsindium111-labeled white blood cellsindium 111-labeled white blood cellsradiolabeled leukocytes111In-leukocytesindium-111-labeled leukocyteindium111-labeled leukocyteindium 111-labeled leukocyte

Beyond the preview

Go deeper on indium In 111 oxyquinoline labeled leukocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on indium In 111 oxyquinoline labeled leukocytes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call